Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Core Insights - Prelude Therapeutics has received FDA clearance for its Investigational New Drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study expected to start in Q2 2026 [1][4] - The company is also advancing its KAT6A degrader program, with an IND filing anticipated in mid-2026 and a Phase 1 study initiation planned for the second half of 2026 [1][5] - Prelude's current cash runway is projected to extend into Q2 2027, with $106 million in cash and equivalents as of December 31, 2025 [1][14] R&D Pipeline Updates - The JAK2V617F mutation is prevalent in 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [3] - Prelude has developed novel allosteric inhibitors that specifically target V617F+ cells, aiming to reduce mutant allele burden and improve treatment outcomes for patients with myeloproliferative neoplasms (MPNs) [3] - The KAT6A oral degrader program targets ER+ breast cancer, with the potential for improved efficacy and tolerability compared to non-selective inhibitors [5] Financial Performance - For the year ended December 31, 2025, Prelude reported a net loss of $99.5 million, or $1.29 per share, a decrease from a net loss of $127.2 million, or $1.68 per share, in the previous year [17][21] - Research and development expenses decreased to $94.3 million from $118.0 million in the prior year, attributed to reduced stock-based compensation and discontinued clinical trials [15] - General and administrative expenses also saw a decline to $22.4 million from $28.7 million, primarily due to lower stock-based compensation and employee-related expenses [16] Upcoming Milestones - The company is on track to have both PRT12396 and PRT13722 in clinical development in 2026, which may lead to significant data catalysts in 2027 [2] - Prelude will participate in the Citizens Life Sciences Conference on March 10, 2026, where key executives will discuss the company's progress and future plans [12]